We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

EU Says Pay-For-Delay Drug Settlements Still Down

Law360 (March 12, 2018, 5:02 PM EDT) -- European Union pay-for-delay settlements between brand pharmaceutical companies and their generic competitors to restrict generic entry into the market “have stabilized at a low level,” European Commission antitrust regulators concluded in a report looking at deals reached in 2016 to resolve drug patent infringement lawsuits.

Settlements restricting generic entry that came with some kind of payoff between brand and generics companies were down to 11 percent of all settlements to resolve drug patent infringement lawsuits, from a 22 percent rate between 2000 and 2008, the commission said...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.